In melanoma, PD-1 inhibitors (nivolumab, pembrolizumab) were mainly linked to thyroid dysfunction (40–45%) and autoimmune diabetes (10–15%), while anti-CTLA-4 agents (ipilimumab, tremelimumab) were predominantly associated with hypophysitis (up to 60%) and adrenal insufficiency (6–11%). The gene discussed is CTLA4; the disease is hypophysitis.